The U.S. Food and Drug Administration (FDA) has approved the first-ever long-acting injectable drug for HIV prevention.
HIV Acquisition on PrEP Rare, With Some Drug Resistance High Levels of Prevention-Effective Adherence to HIV PrEP PrEP During COVID-19: 5 Things to Know CommentsWhat to Read Next on MedscapeSpecial Coverage: COVID-19 Latest Perspective Guidelines Drugs & Diseases Global Coverage Additional Reso...
HIV infectionsORAL drug administrationDESCRIPTIVE statisticsPRE-exposure prophylaxisThe introduction of injectable HIV pre-exposure prophylaxis (PrEP) has the potential to significantly change the biomedical HIV prevention landscape. However, effective implementation will require health care provide...
The task force gave oral PrEP (taken as daily tablets) an A grade in 2019. The update would add another HIV prevention option for folks who prefer not to take the tablets. Increasing the options and availability will also help address health inequities, noted the USPSTF. “Many people who ...
Therefore, manageable drug–drug interactions with dose adjustments should be expected as a minimum. These restrictions are particularly important for the long-acting injectable medicines. In HIV PrEP, one of the main reasons for the successful deployment of injectable cabotegravir is the relative ...
The unique mechanism of action, pharmacokinetics, and safety and efficacy of lenacapavir support its use for the management of MDR HIV-1 infection. Current studies are ongoing to evaluate the potential use of subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP). Future studies will confirm...
Oral pre-exposure prophylaxis (PrEP) is highly effective at reducing HIV transmission risk and is CDC recommended for many gay, bisexual, and other men who have sex with men (GBM). We sought to investigate awareness of and preference for using long-acting injectable PrEP (LAI-PrEP) among GBM...
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often...
The impact of pre-exposure prophylaxis (PrEP) on slowing the global HIV epidemic hinges on effective drugs and delivery platforms. Oral drug regimens are the pillar of HIV PrEP, but variable adherence has spurred development of long-acti... FP Pons-Faudoa,ND Trani,S Capuani,... - 《Science...
Approval of the first injectable PrEP product (cabotegravir) provides an exciting addition to oral PrEP that could encourage those not currently on PrEP to use it. However, few studies have explored interest in injectable cabotegravir among those at increased risk who are not currently on PrEP....